BridgeMD
Role of the noradrenergic system in the regulation of learning dynamics: evaluation of the effect of a low-dose selective noradrenaline reuptake inhibitor (NOISYXETINE)
EU CTIS ID: 2025-520959-90-00
What this study is testing
To characterize the role of the noradrenergic system in the regulation of learning dynamics in healthy subjects, by comparing the behaviour of the subject during learning (in a stable accumulation task and in a changing accumulation task), their pupil diameter, and their electroencephalographic (EEG) responses, after taking a single dose of atomoxetine (40 mg) and placebo
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 to 39 years old
- Right-handed, assessed by the Edinburgh scale
- Written signed informed consent
- Subject covered by the social security system
You likely can't join if
- Pregnant, parturient or breastfeeding woman
- Person subject to a legal protection measure or unable to express consent
- Known intolerance to atomoxetine
- Need to wear glasses and/or lenses to obtain normal vision
- Subject in an exclusion period or enrolled in an interventional study
- First-degree family history of axis I disorder (DSM-IV-TR), excepted unipolar mood and anxiety disorders with OCD
See the full eligibility criteria
- Age 18 to 39 years old
- Right-handed, assessed by the Edinburgh scale
- Written signed informed consent
- Subject covered by the social security system
- Pregnant, parturient or breastfeeding woman
- Person subject to a legal protection measure or unable to express consent
- Known intolerance to atomoxetine
- Need to wear glasses and/or lenses to obtain normal vision
- Subject in an exclusion period or enrolled in an interventional study
- First-degree family history of axis I disorder (DSM-IV-TR), excepted unipolar mood and anxiety disorders with OCD
- Personal history of axis I disorder (DSM-IV-TR) in the 6 months preceding the study entry
- Dependence on a psychoactive substance in the 12 months preceding the study entry, excluding nicotine, any behavioural disorder incompatible with a 2-hour electroencephalographic recording
- Neuro/psychotropic treatment ongoing or stopped less than 1 month ago
- Personal history of neurological pathology (e.g.: congenital malformation, benign or malignant tumour, degenerative disease of the central nervous system (CNS), epilepsy, inflammatory or infectious disease of the CNS, etc.)
- Personal history of chronic disease of infectious, neoplastic, vascular, dysimmune or inflammatory, metabolic or endocrine, degenerative or genetic aetiology. In particular, angle-closure glaucoma, pheochromocytoma, known high blood pressure or measured blood pressure greater than 140/90 mm Hg at baseline, congenital heart disease, known ischemic heart disease, known heart failure, supraventricular or ventricular heart rhythm disorder, nephropathy, known liver disease and any pathology likely to be aggravated by an increase in blood pressure
- Any medical treatment in the month preceding the study entry, apart from effective contraceptive treatment
- Subject deprived of liberty by a judicial or administrative decision
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.